{"Clinical Trial ID": "NCT00244933", "Intervention": ["INTERVENTION 1:", "- Gemcitabine & Genistein", "Gemcitabine, genistine (Novasoy), tumour biopsy Gemcitabine IV-1000mg/m2: Days 1 and 8 every 21 days: Novasoy Orally-100 mg twice/day for 7 days; twice/day on Days 1-21 every 21 days."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A breast cancer confirmed histologically or cytologically", "Stage IV typology", "Clinical and/or radiological evidence of metastatic disease", "A Measurable Disease", "\u00b7 Prior radiation therapy is permitted provided there is 1 measurable disease site outside the radiation field.", "No active CNS metastases", "Previously treated CNS metastases are allowed provided the disease is stable for 3 months without steroids or anti-seizure drugs.", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Gender", "Women", "Status of menopause", "Unspecified", "State of play", "SWOG 0-2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - No.", "Life expectancy", "Unspecified", "Haematopoietic", "Absolute number of neutrophils 1,500/mm3", "Number of platelets 100 000/mm^3", "Hemoglobin 10 g/dL", "Hepatic", "Bilirubine 3.0 mg/dL", "ASAT and ALT 2.5 times the upper limit of normal", "Renal", "Creatinine 1.5 mg/dL", "Other", "No pregnancy or breast-feeding", "Fertile patients should use effective contraception", "No serious systemic disorder that would prevent compliance with the study", "No history of malignancy other than cervix carcinoma or skin cancer of basal or squamous cells in complete remission", "No unsolved bacterial infection requiring antibiotic treatment", "No known HIV-1 positivity", "THERAPE PRIOR CONCURENT:", "Biological therapy", "At least 3 weeks since previous biological therapy", "- Chemotherapy", "Previous authorised adjuvant chemotherapy", "Prior treatment with adjuvant or neoadjuvant based on taxane or treatment with taxane for metastatic disease is permitted.", "The patient must have failed treatment within 2 years of completion of treatment.", "At least 3 weeks since previous chemotherapy", "No more than 2 prior cytotoxic chemotherapys for metastatic diseases", "No previous gemcitabine hydrochloride", "No other concomitant chemotherapy", "Endocrinotherapy", "See Disease Characteristics", "At least 2 weeks since previous hormonal treatment and no concomitant hormonal treatment", "\u2022 Must have documented the progression of the disease during prior hormonal treatment", "Radiotherapy", "See Disease Characteristics", "At least 4 weeks after previous and recovered radiotherapy", "No simultaneous radiotherapy", "Surgery", "At least 3 weeks since the previous operation", "Other", "At least 3 weeks since previous experimental treatment", "At least 1 week since previous soya supplements (e.g. soy-based, liquid or concentrated pills)", "\u2022 Food soy as part of a meal (e.g. tofu) allowed once a week", "No nutritional supplement, herbal agent or high dose of antioxidants (e.g. vitamins C, D or E) that may interact with, antagonize, modify or mimic the potential effects of gemcitabine hydrochloride or genistine", "Only one daily multivitamin is allowed", "No other concomitant immunotherapy", "No other concomitant experimental medicinal products", "\u2022 Concomitant anticoagulants, appetite stimulants and replacement steroids allowed"], "Results": ["Performance measures:", "Objective response rate by RECIST criteria", "By Response Assessment Criteria in Solid Tumours Criteria (RECIST v1.0) for Targeted and MRI-Assessed Injuries: complete response (CR), elimination of all target lesions; partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions; overall response (RO) = CR + PR.", "Duration: every 2 courses until disease progression or death, up to 24 weeks", "Results 1:", "Title of the arm/group: Gemcitabine & Genistein", "Description of the arm/group: Gemcitabine, genistein (Novasoy), Biopsy of the Gemcitabine IV-1000mg/m2 tumours: Days 1 and 8 every 21 days: Novasoy Orally-100 mg twice/day for 7 days; twice/day for 1-21 days every 21 days.", "Total number of participants analysed: 17", "Type of measurement: Number", "Unit of measurement: participants 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/19 (26.32 per cent)", "3/19 pain (15.79%)", "White blood cells (WBC) 5/19 (26.32%)", "Hemoglobin (Hgb) 1/19 (5.26%)", "Absolute number of neutrophils (ANC) 5/19 (26.32%)", "3/19 blisters (15.79 per cent)", "- High Aspartate Aminotransferase (AST) 1/19 (5.26%)", "- Alanine aminotransferase high (ALT) 1/19 (5.26%)", "Dyspnoea 3/19 (15.79 per cent)"]}